Oncopeptides : Handelsbanken Healthy Hour - presentation

N

Presentation Handelsbanken HealthyHour

September 15, 2021

Disclaimer

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Oncopeptides AB (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information").

On 26 February 2021, the U.S. Food and Drug Administration ("FDA") approved PEPAXTO® (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. This indication has been granted under accelerated approval based upon data from the HORIZON study. Melflufen is not approved by any other registration authorities.

Melflufen is an abbreviated form of the international non-proprietary name (INN) melphalan flufenamide

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future.

No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

2

Agenda

• Introduction - Marty J Duvall, CEO
• Presentation of OCEAN data - Klaas Bakker, MD, PhD
• Presentation of data from PORT - Klaas Bakker
• Financials - Anders Martin-Löf, CFO
• Closing remarks - Marty J Duvall
• Q&A

3

Key messages

• Q2 - first full quarter with revenue
• • Q2 net sales of SEK 66.4 M ($7.2M) and YTD net sales of SEK 85.7 M ($10.2M) since launch in mid-March
  • Double-digitdemand growth on a month-to-month basis
  • Difficult to predict future sales due to FDA issue
• Data presented at IMW encouraging
• • OCEAN phase 3 study
  • PORT phase 2 study
• Near-termfocus is to reach an agreement with the FDA
• • ODAC meeting to be held on October 28
  • Various outcomes from FDA review possible
• Regulatory process with the EMA proceeding according to plan

4

PEPAXTO strategy - Two-pronged approach

Becoming a foundational treatment in RRMM

Driving change in today's RRMM treatment paradigm where drug classes are "recycled"

Existing classes				New classes/MoA
New MOAs
	New MOAs
IMIDs			PEPAXTO (2021)
• Thalidomide (1999)			1	Belantamab (2020)
• Lenalidomide (2003)
		Selinexor (2019)
• Pomalidomide (2013)
	2
PIs		Abecma (2021)
• Bortezomib (2003)
• Carfilzomib (2012)
• Ixazomib (2015)	Recycling		Recycling
CD-38
Old Classes		Old Classes
• Daratumumab (2015)

• Isatuximab (2020)

1	Become the
		treatment of choice
		for appropriate and
		indicated patients
2	Expand market for new
		MOAs and minimize
		"recycling" of failed
		drug classes

TodayFuture

5